JOURNAL OF INTERNATIONAL CRISIS AND RISK COMMUNICATION RESEARCH
ISSN: 2576-0017
2024, VOL 7, NO S8

Cellular Responses to Ionizing Radiation: Mechanisms of DNA Repair and Mutation

Shrooq Mohammad Alqahtani[1], Hanan Ahmad Alassiri[1], Mashael Saeed Mohammed Alshahrani[1], Nadiya Ali Alahmari[1], Norah Zoraib Saeed Alshahrani[1], Amani Ali Alqahtani[1], Alaa Mohammad Alshahrani[1], Fatimah Abdulrahman Ali Asiri[1], Huda Mohammed Menshet[1], Eman Mohammed Modawi[1], Alanood Mathkar Alqahtani[1]

1 Radiology Specialist, Khamis Mushayt Maternity and Children's Hospital

Abstract:

Ionizing radiation (IR) induces various cellular responses that significantly impact DNA integrity, triggering a cascade of mechanisms aimed at repairing damage and maintaining genomic stability. DNA can suffer different types of damage from IR, including single-strand breaks (SSBs), double-strand breaks (DSBs), and base modifications. Cellular responses involve intricate repair pathways such as base excision repair (BER), nucleotide excision repair (NER), and homologous recombination (HR), which work to restore genetic fidelity. When DNA repair mechanisms are overwhelmed or erroneous, mutations can arise, influencing cell function and potentially leading to carcinogenesis. Cells possess complex signaling pathways, such as the p53 tumor suppressor pathway, that regulate the cell cycle and apoptosis in response to severe damage, thereby influencing cell fate and survival.

Despite these sophisticated reparative processes, not all radiation-induced DNA damage is corrected. Mutagenesis can occur if repair mechanisms fail or if errors are introduced during repair, leading to permanent changes in the DNA sequence. These mutations can manifest in various forms, including point mutations, insertions, deletions, and chromosomal rearrangements. The accumulation of such mutations in critical genes related to cell cycle control and apoptosis can contribute to the development of cancer over time. Understanding the precise mechanisms by which cells respond to ionizing radiation is crucial for improving radiotherapy strategies, developing protective measures, and assessing cancer risk associated with environmental exposure to radiation.

Keywords: Ionizing radiation, DNA repair, nucleotide excision repair, mutations, carcinogenesis, environmental exposure, radiotherapy.

Introduction:

The interaction of ionizing radiation (IR) with cellular matter results in a series of complex biological responses, predominantly centered on the damage inflicted upon genetic material. Ionizing radiation is characterized by its capability to generate charged particles, which can displace electrons from atoms and molecules, leading to a spectrum of damage within biological systems, particularly within DNA. The significance of understanding these cellular responses lies not only in the context of radiation therapy used in the treatment of cancer but also in the broader implications for environmental exposure, nuclear accidents, and radiological protection. This introduction aims to elucidate the intricate mechanisms underlying cellular responses to ionizing radiation, focusing specifically on DNA repair pathways and the potential for mutation as a byproduct of these processes [1].

When cells are exposed to ionizing radiation, several types of DNA damage can occur, the most prevalent being single-strand breaks (SSBs) and double-strand breaks (DSBs). Single-strand breaks result from the direct interaction of radiation with the DNA backbone, while double-strand breaks, which are substantially more detrimental, can arise either directly from IR or indirectly following the formation of reactive oxygen species (ROS). DSBs pose a particular challenge for cellular integrity as they can lead to genomic instability, cell cycle arrest, apoptosis, or mutagenesis if not properly repaired. The response to such damage is largely dictated by the type of cells involved—their stage in the cell cycle, the efficiency of their DNA repair mechanisms, and the presence of specific signaling pathways that govern cell fate in response to stress [2].

Cells have evolved an elaborate suite of DNA repair mechanisms to counteract the harmful effects of ionizing radiation. These repair pathways can broadly be categorized into two main types: homologous recombination (HR) and non-homologous end joining (NHEJ). Homologous recombination is a high-fidelity repair mechanism that utilizes a sister chromatid as a template to accurately repair the damage, while non-homologous end joining directly rejoins the broken ends of DNA but is inherently error-prone. The choice of repair pathway can significantly influence the outcome of damage; for instance, successful HR can restore original genetic information, whereas NHEJ can lead to deletions or insertions, ultimately contributing to mutation [3].

In addition to these canonical repair pathways, a variety of accessory processes and alternative repair mechanisms also play crucial roles in maintaining genomic stability following exposure to ionizing radiation. These include base excision repair (BER) and nucleotide excision repair (NER), which are primarily responsible for correcting smaller lesions that may not be as severe as SSBs or DSBs but can still precipitate mutagenesis if left unrepaired. Furthermore, the recognition and signaling of DNA damage are mediated by abundant proteins such as ATM (Ataxia Telangiectasia Mutated), ATR (ATM and Rad3-related), and p53, which not only activate repair pathways but also induce cell cycle arrest or apoptosis in cases of irreparable damage [4].

Despite the presence of robust DNA repair mechanisms, the occurrence of mutations following ionizing radiation exposure is an inevitable risk. Mutations can arise as a consequence of erroneous repair processes, especially through NHEJ repair, where misalignment of broken ends may lead to sequence alterations. These mutations can manifest in various forms, including point mutations, insertions, deletions, and chromosomal rearrangements, each carrying potential implications for cellular function and organismal health. Moreover, the long-term consequences of these mutations can contribute to carcinogenesis, as mutations in critical genes involved in cell cycle regulation and apoptosis may facilitate uncontrolled cellular proliferation [5].

The study of mutations resulting from ionizing radiation exposure extends beyond a single cellular context; it encompasses considerations of tissue-specific responses and inter-individual variability. Factors such as genetic predispositions, age, and environmental influences can modulate the efficiency of DNA repair mechanisms and thus affect mutation prevalence. Understanding these variables is crucial for improving therapeutic strategies in radio-oncology and for assessing risks associated with occupational and environmental exposure to radiation [6].

Types of DNA Damage Induced by Ionizing Radiation:

Ionizing radiation (IR) is a high-energy form of electromagnetic radiation or particles that possesses enough energy to ionize atoms and molecules. This ability to displace electrons from atoms can lead to various biological effects, most notably the damage of cellular macromolecules such as DNA. Understanding the types and mechanisms of DNA damage induced by ionizing

radiation is critical, as it has significant implications for fields ranging from radiation therapy in cancer treatment to radiation protection for workers and the general public [7].

DNA, or deoxyribonucleic acid, is composed of two long strands that coil around each other, forming a double helix. Each strand consists of a sugar-phosphate backbone and nucleotide bases: adenine (A), thymine (T), cytosine (C), and guanine (G). The sequence of these bases encodes genetic information critical for cellular function, development, and reproduction. Any change or damage to this genetic blueprint can disrupt cellular processes, leading to mutations, cancer, or cell death [8].

Ionizing radiation can come from various sources, including cosmic rays, radioactive materials, and medical devices like X-ray machines. When living tissue is exposed to ionizing radiation, energy is imparted to atoms and molecules within the cells, leading to the formation of reactive species and various forms of DNA damage [9].

Direct vs. Indirect DNA Damage

Ionizing radiation can induce DNA damage both directly and indirectly.

1. **Direct DNA Damage**: This occurs when ionizing radiation directly interacts with the DNA molecule, causing structural alterations. Types of direct damage include single-strand breaks (SSBs) and double-strand breaks (DSBs). Single-strand breaks occur when one of the two DNA strands is severed, which can lead to replication errors if not properly repaired. However, double-strand breaks are more severe, as they involve the breaking of both strands of the DNA helix. DSBs can result in chromosomal aberrations, such as translocations, deletions, and fusions. Studies suggest that DSBs are among the most lethal forms of DNA damage and are a significant contributor to cell death and genomic instability [10].
2. **Indirect DNA Damage**: This occurs through free radicals generated by the interaction of ionizing radiation with water molecules—a process known as radiolysis of water. The ionization of water produces various reactive oxygen species (ROS), such as hydroxyl radicals, superoxide, and hydrogen peroxide. These ROS can then diffuse to the DNA and react with it, causing different forms of damage, including modified bases, SSBs, and even DSBs. Indirect damage often contributes substantially to the overall DNA damage caused by ionizing radiation and can have far-reaching biological consequences [10].

Types of DNA Damage Induced by Ionizing Radiation

Ionizing radiation causes a spectrum of DNA lesions that can be categorized as follows:

1. **Single-Strand Breaks (SSBs)**: These breaks occur when the phosphodiester bond of one DNA strand is severed, leading to the formation of a free DNA end. While single-strand breaks can be repaired relatively easily via cellular mechanisms like the base excision repair (BER) pathway, they can become a serious threat if encountered during DNA replication [11].
2. **Double-Strand Breaks (DSBs)**: DSBs are considered the most critical type of DNA damage. They can occur directly or indirectly and have profound consequences for the cell. Unlike SSBs, DSBs can lead to the loss of genomic information and chromosomal instability, which may contribute to carcinogenesis if left unrepaired. The cell has several pathways for repairing DSBs, including homologous recombination (HR) and non-homologous end joining (NHEJ); however, errors in these repair mechanisms can lead to mutations [12].
3. **Base Damage**: Ionizing radiation can also induce changes in the chemical structure of the nucleotide bases themselves. This includes modifications such as oxidation, alkylation, or

deamination of bases, which can cause mispairing during DNA replication. Base damage is typically repaired through nucleotide excision repair (NER) or base excision repair (BER) pathways [13].

4. **Cross-Linking**: Although less common than other types of damage, ionizing radiation can cause DNA cross-links, where two strands of DNA become covalently bonded together. This linkage can impede DNA replication and transcription, affecting cellular function. Cross-links can be repaired by specialized repair pathways that are more complex than those typically employed for simpler breaks.
5. **Clustered Damage**: Ionizing radiation often causes clustered DNA damage, where multiple types of lesions occur within a short distance on the DNA strand. This type of damage is particularly challenging for cellular repair machinery due to the close proximity of lesions that may complicate the repair process [13].

Biological Consequences of DNA Damage

The biological repercussions of DNA damage induced by ionizing radiation are vast and can impact cellular function and organismal health in several ways:

1. **Cell Death**: Severe DNA damage can lead to programmed cell death, or apoptosis, to prevent the propagation of damaged cells. While this serves as a protective mechanism, excessive cell death can lead to tissue injury and atrophy [14].
2. **Genomic Instability**: Cells that survive initial DNA damage may undergo mutations during subsequent replication cycles. This genomic instability is a hallmark of cancer development, as it can lead to the accumulation of oncogenic mutations.
3. **Ageing and Teratogenic Effects**: Accumulation of DNA damage over time has been implicated in the ageing process and age-related diseases. Moreover, if ionizing radiation exposure occurs during critical periods of development, it can lead to teratogenic effects, manifesting as congenital disorders or developmental abnormalities.
4. **Increased Cancer Risk**: The link between ionizing radiation and cancer is well-established. Exposure to ionizing radiation has been associated with various cancers, including leukemia, thyroid cancer, and solid tumors. The risk is particularly heightened following high doses of radiation, such as those received during therapeutic treatments or nuclear exposure [14].

Cellular Signaling Pathways in Response to DNA Damage:

DNA is the fundamental blueprint of life, harboring the genetic information required for the development, functioning, growth, and reproduction of organisms. However, this genetic material is constantly under threat from various endogenous and exogenous sources, leading to DNA damage. Factors like ultraviolet (UV) radiation, ionizing radiation, chemical agents, and by-products of cellular metabolism can introduce lesions in the DNA. While these damages are an inevitable consequence of cellular activity and environmental exposure, cells are equipped with sophisticated cellular signaling pathways that detect and respond to such injuries [15].

The DNA Damage Response (DDR)

The DNA damage response (DDR) denotes a complex network of cellular processes that detect DNA lesions and initiate repair. Central to these processes are signaling pathways that activate cellular checkpoints and repair mechanisms, ensuring that the integrity of the genome is maintained. The DDR is primarily executed through three main signaling cascades: the ATM

(Ataxia Telangiectasia Mutated) pathway, the ATR (ATM and Rad3-related) pathway, and the DNA-PK (DNA-dependent protein kinase) pathway [16].

1. **ATM Pathway**: ATM is activated primarily in response to double-strand breaks (DSBs), which are among the most severe forms of DNA damage. Upon DSB detection, ATM undergoes autophosphorylation and subsequently phosphorylates several downstream targets, including the checkpoint kinase Chk2. This phosphorylation triggers a cell cycle arrest primarily at the G2/M checkpoint, preventing the cell from entering mitosis before the damage can be repaired. Additionally, ATM signaling activates repair pathways such as non-homologous end joining (NHEJ) and homologous recombination (HR) to facilitate the repair of the damaged DNA [17].
2. **ATR Pathway**: In contrast to ATM, ATR is primarily activated by single-strand breaks (SSBs) and replication stress. ATR recognizes SSBs and stalled replication forks, leading to its phosphorylation by the Rad17-RFC loading complex. This activation results in the phosphorylation of Chk1, which also contributes to cell cycle checkpoint activation, primarily at the S phase and G2/M transitions. ATR signaling is crucial for maintaining replication fork stability and ensuring proper DNA repair.
3. **DNA-PK Pathway**: The DNA-PK pathway operates primarily in the context of NHEJ, a repair mechanism for DSBs. DNA-PK is a complex consisting of a catalytic subunit (DNA-PKcs) and the Ku protein, which recognizes DSBs. DNA-PK binds to the ends of the broken DNA, facilitating the recruitment of additional repair factors necessary for NHEJ. The phosphorylation events orchestrated by DNA-PKcs lead to cell cycle regulation, apoptosis, and activation of downstream repair mechanisms [18].

Checkpoints and Cell Cycle Regulation

Cell cycle checkpoints serve as critical regulatory nodes ensuring proper cell division and genomic integrity. They act as surveillance mechanisms that assess DNA integrity before cells progress through various phases of the cell cycle. Upon detection of DNA damage, checkpoint kinases like Chk1 and Chk2 inhibit Cyclin-dependent kinases (CDKs) to delay cell cycle progression [19].

- **G1/S Checkpoint**: During the G1 phase, the cell assesses whether the DNA is intact before proceeding to DNA synthesis. If damage is detected, the p53 protein, a crucial tumor suppressor, is activated. p53 induces the expression of p21, a CDK inhibitor that halts the transition from G1 to S phase, allowing time for repair processes to take place.
- **G2/M Checkpoint**: The G2 checkpoint helps ensure that DNA repair processes are completed before the cell enters mitosis. Chk1 and Chk2 mediate this checkpoint, inhibiting the activity of CDK1, thereby delaying mitosis. If the damage is irreparable, p53 can promote apoptosis, ensuring that cells with extensive damage do not propagate [19].

Repair Mechanisms

The cellular response to DNA damage not only hinges on signaling pathways but also employs multiple DNA repair mechanisms tailored to different types of damage. Two primary repair strategies are NHEJ and HR [20].

1. **Non-homologous End Joining (NHEJ)**: This repair pathway is predominant for DSB repair, especially in non-dividing cells. NHEJ directly ligates the ends of broke DNA without the need for homologous sequences. Although it is relatively quick, it may introduce mutations and genomic instability.
2. **Homologous Recombination (HR)**: This process is more accurate than NHEJ and primarily occurs during the S and G2 phases of the cell cycle when a sister chromatid is available for repair. HR involves strand invasion, requiring extensive end resection of

DSBs and the use of homologous sequences to guide accurate repair. This precision is crucial in maintaining genomic stability [20].

Systemic Consequences of DNA Damage Signaling

The DDR is not merely an isolated response; the signaling pathways activated in response to DNA damage have broader systemic implications. Persistent DNA damage signals can trigger various outcomes, including:

- **Cell Cycle Arrest**: Temporary pausing of the cell cycle extends the timeframe for repair.
- **Cellular Senescence**: In response to irreparable DNA damage, cells may enter a state of permanent growth arrest, which plays a role in aging and cancer development.
- **Apoptosis**: High levels of DNA damage or ineffective repair can lead to programmed cell death, preventing the propagation of potential oncogenic mutations.

Furthermore, failure or dysregulation of these signaling pathways can lead to increased susceptibility to cancer, neurodegenerative diseases, and other age-related conditions. The understanding of these pathways also opens avenues for therapeutic interventions, especially in cancer treatment, where exploiting deficiencies in the DDR can selectively target tumor cells while sparing normal cells [21].

Mechanisms of DNA Repair: Overview of Repair Pathways:

DNA, the fundamental hereditary material in all living organisms, endures continuous assaults from both endogenous and exogenous sources, which can lead to a variety of lesions that compromise its structural integrity. A failure to repair these lesions can result in mutations that may contribute to diseases such as cancer, aging, and genetic disorders. Thus, understanding the myriad pathways through which cells rectify DNA damage is crucial for elucidating mechanisms of genomic stability and their implications in health and disease [22].

Before delving into repair mechanisms, it is essential to comprehend the types of DNA damage that can occur. DNA lesions can be broadly categorized into two groups: single-strand breaks (SSBs) and double-strand breaks (DSBs). SSBs arise from oxidative stress, replication errors, or exposure to ionizing radiation and chemical agents. Conversely, DSBs, which are particularly deleterious, can occur due to high-energy radiation, chemical-induced damage, or during DNA replication and recombination. Further classifications of DNA damage include base alterations, such as methylation or deamination, which can disrupt the normal sequence of nucleotides [23].

The cell employs an array of DNA repair mechanisms, including base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), homologous recombination (HR), and non-homologous end joining (NHEJ). Each of these pathways has unique roles and mechanisms, which are tailored to address specific types of DNA damage [24].

Base excision repair is pivotal for repairing non-helix-distorting base lesions, primarily resulting from oxidation, alkylation, or deamination. The core process involves the recognition of a damaged base by a specialized enzyme known as DNA glycosylase. Once the damaged base is excised, an AP (apurinic/apyrimidinic) site is left behind. The action of an AP endonuclease follows, which cleaves the sugar-phosphate backbone, creating a SSB. DNA polymerase then fills in the gap with the correct nucleotide, and DNA ligase seals the final nick. This seemingly simple yet efficient mechanism highlights the remarkable specificity of BER in maintaining genetic fidelity [25].

Nucleotide excision repair addresses bulky adducts that distort the DNA helix, such as those resulting from UV radiation or chemical mutagens. The NER pathway operates through two sub-

pathways: global genomic repair (GGR) and transcription-coupled repair (TCR). GGR scans the entire genome, while TCR specifically targets lesions on actively transcribed genes. Both pathways involve damage recognition, unwinding of the DNA helix, dual incisions around the lesion, and excision of a short single-strand fragment. The gap is then filled by DNA polymerase and sealed by ligase. Deficiencies in NER have been linked to several disorders, including Xeroderma Pigmentosum, underscoring its significance in maintaining genomic stability.

Mismatch repair is crucial for correcting base-pair mismatches and insertion-deletion loops that occur during DNA replication. The MMR machinery identifies the incorrect base pairing and a complex of MutS and MutL proteins is involved in distinguishing the newly synthesized strand from the template strand. Subsequently, the error is excised from the new strand, followed by resynthesis mediated by DNA polymerase and ligation. Deficiencies in MMR are implicated in hereditary nonpolyposis colorectal cancer (HNPCC), emphasizing its importance in preventing mutagenesis [26].

Homologous recombination is a sophisticated mechanism used to repair DSBs, ensuring high fidelity due to its reliance on a homologous template. When a DSB occurs, the damaged ends are processed to generate single-stranded DNA (ssDNA) overhangs. This ssDNA is coated by RAD51 protein, which facilitates the search for homologous sequences on an undamaged sister chromatid. Once a homologous template is located, the DNA strand invades the template, leading to synthesis-dependent strand annealing. By utilizing homologous sequences, HR minimizes the risk of introducing mutations and is particularly active during the late S and G2 phases of the cell cycle when sister chromatids are available for repair [27].

In contrast to HR, non-homologous end joining provides a quicker yet less accurate method for repairing DSBs. This pathway occurs predominantly in the G1 phase of the cell cycle, where sister chromatids are not available. The process involves the recognition of the DSB ends by the KU protein complex, which stabilizes the broken ends and recruits the DNA-PKcs protein to form a repair complex. The ends are then processed, followed by ligation. NHEJ is vital for maintaining the integrity of the genome, though it can introduce insertions and deletions at the repair site, potentially leading to mutations [28].

While these repair mechanisms operate distinctly, they are not entirely independent. There is increasing recognition of crosstalk between pathways, particularly in response to varying forms of DNA damage and cellular conditions. For instance, the decision between utilizing HR and NHEJ for DSB repair is influenced by cell cycle stage, the complexity of the break, and the availability of homologous templates. Additionally, coexistence of repair pathways further ensures cellular survival even when one pathway is compromised. For example, defects in HR can lead to reliance on NHEJ, making understanding these interactions critical for therapeutic strategies, especially in cancer treatment [29].

Homologous Recombination and Non-Homologous End Joining:

DNA is the molecular blueprint for life, encoding the instructions for the development, functioning, and reproduction of all known organisms. However, the integrity of DNA can be compromised by various internal and external factors, leading to breaks in the double-stranded DNA structure. Such DNA damage, if unrepaired, can result in mutations, genomic instability, and diseases, including cancer. To combat this, cells have evolved sophisticated DNA repair mechanisms, of which homologous recombination (HR) and non-homologous end joining (NHEJ) are two crucial pathways [29].

Before delving into the specifics of HR and NHEJ, it is essential to understand the types of DNA damage that can occur. DNA can sustain two primary types of double-strand breaks (DSBs): those induced by exogenous factors—such as radiation and chemicals—and those arising from endogenous processes, such as replication errors and oxidative stress. DSBs are particularly dangerous because they can lead to chromosomal rearrangements, loss of genetic information, or cell death if not accurately repaired. Thus, cells must respond rapidly and effectively to restore genetic stability [30].

Homologous Recombination

Homologous recombination is a precise and error-free repair mechanism primarily utilized during the late S and G2 phases of the cell cycle, when a sister chromatid is available as a template. It is characterized by several stages:

1. **Recognition and processing of the break**: DSBs are detected by the cell's repair machinery, which involves a complex of proteins known as the MRN complex (Mre11-Rad50-Nbs1). This complex aids in the resection of DNA ends, producing single-stranded DNA (ssDNA) overhangs [31].
2. **ssDNA binding and strand invagination**: The ssDNA is rapidly coated by a protein called RPA (Replication Protein A), which stabilizes it. Subsequently, another protein known as RAD51 replaces RPA to form a nucleoprotein filament. RAD51 plays a crucial role in searching for complementary sequences on the homologous chromosome or sister chromatid.
3. **Strand invasion**: Once RAD51 has identified a match, the invading strand of ssDNA displaces one strand of the homologous DNA, forming a structure known as a displacement loop (D-loop). This process facilitates the alignment of homologous sequences.
4. **DNA synthesis**: The repair DNA polymerase can now extend the 3’ end of the invading strand, using the homologous DNA as a template, allowing for the accurate restoration of genetic information.
5. **Resolution of the repair structure**: The final steps involve branch migration, resolution of intermediates, and ligation to restore a continuous DNA molecule [31].

The beauty of HR lies in its fidelity; by utilizing a homologous template, the risks of mutations during the repair are significantly reduced. HR not only repairs DSBs but also plays a vital role in genetic recombination during meiosis, contributing to genetic diversity in sexually reproducing organisms.

Non-Homologous End Joining

Conversely, non-homologous end joining is an alternative repair pathway characterized by its speed and efficiency but notably greater propensity for errors. NHEJ operates primarily in the G1 phase of the cell cycle when there is no sister chromatid available. The steps in NHEJ involve:

1. **End recognition and processing**: DSBs are recognized by the Ku protein complex, which consists of Ku70 and Ku80 subunits. Following recognition, Ku binds to the DNA ends and facilitates the recruitment of additional proteins involved in the NHEJ process [32].
2. **DNA end processing**: The ends of the broken DNA may be further processed by nucleases or polymerases, depending on whether they are compatible for direct ligation. This processing can lead to the trimming of overhangs or filling in of gaps.
3. **Ligation**: The final step in NHEJ involves the enzyme DNA ligase IV, along with its associated factors, such as XRCC4, which brings the two DNA ends together and catalyzes the formation of phosphodiester bonds to complete the repair [32].

Unlike HR, NHEJ does not copy genetic information from a template, making it prone to inserting or deleting nucleotides at the repair site. This can lead to mutations, chromosomal translocations, and other forms of genomic instability, which can contribute to oncogenesis.

Biological Significance and Implications

The balance between HR and NHEJ is crucial for maintaining genomic stability. Different cell types and stages of the cell cycle preferentially utilize one pathway over the other. For instance, proliferating cells are more likely to engage in HR due to the presence of sister chromatids, while quiescent or non-dividing cells primarily rely on NHEJ [33].

Moreover, efficient repair mechanisms are pivotal for cancer prevention. Defects in HR are linked to certain types of breast and ovarian cancers, particularly those associated with mutations in the BRCA1 and BRCA2 genes. These genes are integral to the HR process, and their dysfunction results in a reliance on NHEJ, enhancing the potential for mutagenesis and tumorigenesis [34].

In contrast, some cancers may exploit NHEJ to gain a survival advantage by promoting genomic diversity, enabling rapid adaptation to therapies, and facilitating metastasis. Understanding these mechanisms further enhances the potential for targeted therapies. For example, the efficacy of PARP inhibitors has been recognized in BRCA-related cancer treatment, illustrating the relevance of elucidating DNA repair pathways in clinical settings [34].

The Role of p53 in DNA Damage Response and Cell Fate:

The integrity of genetic material is paramount for the survival and proper functioning of an organism. DNA damage, stemming from environmental factors, metabolic processes, or replication errors, poses a significant threat to cellular function and organismal health. Cells have evolved complex mechanisms to detect and respond to DNA lesions, ensuring that such damage does not propagate to subsequent generations of cells. One of the most crucial players in this response is the tumor suppressor protein p53. Often referred to as the "guardian of the genome," p53 orchestrates a wide array of cellular processes linked to DNA damage response (DDR) and ensuing cell fate decisions. Understanding the multifaceted role of p53 provides insights into cancer biology, aging, and therapeutic interventions [35].

The discovery of p53 can be traced back to the early 1970s, when it was first identified as a protein that binds to the simian virus 40 (SV40) large T-antigen. Subsequent research revealed that p53 is not only a viral target but plays a critical role in cellular processes, primarily in tumor suppression. The p53 gene, located on chromosome 17 in humans, encodes a transcription factor that can regulate the expression of hundreds of target genes involved in cellular stress responses, cell cycle regulation, and apoptosis.

p53 functions predominantly as a sequence-specific transcription factor, activating or repressing a multitude of genes involved in key pathways. Under physiological conditions, p53 is maintained at low levels in the cell, primarily due to its rapid degradation by the proteasome. However, in response to various stress signals, particularly DNA damage, p53 protein levels increase through post-translational modifications that prevent its degradation. These modifications include phosphorylation and acetylation, which enhance its stability and transcriptional activity [36].

The p53-mediated DDR is a critical response pathway activated upon the detection of DNA damage. p53 integrates signals from multiple cellular stressors, allowing it to coordinate an appropriate response. Upon activation, p53 induces cell cycle arrest, which allows time for DNA repair mechanisms to act on the damaged DNA. It achieves this primarily through transcriptional activation of target genes involved in cell cycle regulation, such as p21^CIP1/WAF1, which

inhibits cyclin-dependent kinases (CDKs) and halts cell cycle progression at the G1/S or G2/M checkpoints [37].

In cases where the damage is too severe or irreparable, p53 can activate apoptotic pathways through the upregulation of pro-apoptotic factors such as Bax and PUMA, while simultaneously repressing anti-apoptotic proteins like Bcl-2. This decision to induce apoptosis prevents the propagation of cells with damaged DNA, thereby serving as a safeguard against tumorigenesis. Additionally, p53 can direct cells towards a state called senescence—a permanent form of cell cycle arrest that prevents division while allowing cells to remain metabolically active. Senescence is increasingly recognized as a vital mechanism in tumor suppression and aging.

p53 as a Gatekeeper of Cellular Fate

The ability of p53 to influence cell fate decisions highlights its role as a central regulatory hub amidst various cellular stressors. The outcomes of p53 activation—whether cell cycle arrest, senescence, or apoptosis—are determined by several factors, including the intensity and duration of the stress signal, the extent of DNA damage, and the cellular context [38].

1. **Cell Cycle Arrest**: When DNA damage is detected but deemed repairable, cellular pathways activate p53 to induce cell cycle arrest. The expression of p21, a potent CDK inhibitor, halts the cell cycle, providing the cellular machinery with the necessary time to repair the DNA. If successful, the cell can resume division; however, failure of repair mechanisms can lead to a shift in p53's role to pro-apoptotic activities.
2. **Apoptosis**: In situations where damage is irreparable, the p53 pathway guides the cell towards apoptosis. Apoptosis is a programmed cell death mechanism crucial for eliminating potentially cancerous cells. The decision to undergo apoptosis rather than cell cycle arrest stems from a variety of signals, including the type and extent of DNA damage, the cellular context, and the presence of other regulatory factors [39].
3. **Senescence**: An intriguing aspect of p53's role in cell fate is its capacity to drive cells into senescence. Senescent cells remain metabolically active but lose the ability to proliferate. This state can act as a double-edged sword; while it prevents the propagation of damaged DNA, the accumulation of senescent cells in tissues has been implicated in aging and various age-related diseases [39].

Implications of p53 Dysregulation

Given p53’s pivotal role in controlling cell fate in the face of DNA damage, it is not surprising that mutations or alterations in p53 are frequently observed in various cancers. Approximately half of all human tumors harbor mutations in the TP53 gene, underscoring its significance in tumorigenesis. Mutated p53 often results in a loss of function, allowing cells to escape normal checkpoints, accumulate further mutations, and ultimately contribute to cancer progression. Additionally, some mutant forms of p53 may gain oncogenic properties, promoting tumor growth and metastasis [40].

Beyond cancer, dysfunction in p53 signaling pathways has implications for aging and age-related diseases. The accumulation of senescent cells, often resulting from chronic p53 activity in response to persistent stress, can lead to localized inflammation and tissue dysfunction. This connection between p53, cellular senescence, and aging is an active area of research with potential therapeutic implications [40].

Given its central role in maintaining genomic stability, p53 has emerged as a prime target for cancer therapies. Strategies aimed at reactivating mutant p53 or enhancing its functions include

small molecules, gene therapy, and immunotherapy approaches. For instance, compounds that restore the function of mutant p53 may reinstate its ability to induce apoptosis in tumor cells, while p53-based vaccines aim to stimulate the immune system to target p53-deficient cells.
Furthermore, research into modulating p53 activity in the context of aging is gaining traction. Interventions that could effectively promote senescence in cancerous tissues while preserving the functions of healthy cells could provide a dual benefit in combating cancer and age-related pathologies [41].

Mutagenesis: Consequences of DNA Repair Failure:
Mutagenesis, the process by which changes occur in the DNA sequence, presents a fundamental biological challenge with far-reaching consequences. As organisms experience various extrinsic and intrinsic threats—ranging from environmental exposure to chemical agents and radiation—their cellular machinery must respond effectively to maintain genomic stability. One of the critical functions in this context is the DNA repair system. When this intricate network of repair mechanisms is compromised, the resulting failure can lead to an array of mutations that cascade into serious biological consequences [42].
Mutagenesis can be classified into several categories based on origin, with two primary classifications being spontaneous and induced mutagenesis. Spontaneous mutations arise naturally during DNA replication or due to the inherent instability of DNA; for example, tautomeric shifts can lead to base-pair mismatches. On the other hand, induced mutations result from external factors, such as ultraviolet (UV) irradiation, ionizing radiation, or chemical exposures like alkylating agents that alter DNA structure [42].
Mutations can manifest in various forms, including point mutations (single nucleotide changes), insertions, deletions, duplications, and larger chromosomal rearrangements. The effects of these mutations range from benign (silent mutations) to deleterious (nonsense or frameshift mutations), and they play a critical role in the evolutionary mechanisms driving diversity among organisms.
DNA Repair Systems
The biological importance of DNA repair cannot be overstated. Cellular machinery is equipped with several repair pathways to resolve DNA damage, each adapted to specific types of lesions. The primary repair mechanisms include:

1. **Base Excision Repair (BER):** This mechanism targets small, non-helix distorting base lesions caused by oxidative stress or deamination. Enzymes remove damaged bases, and DNA polymerase fills the gap followed by ligase sealing [43].
2. **Nucleotide Excision Repair (NER):** This pathway is invoked primarily in response to helix-distorting lesions such as pyrimidine dimers induced by UV light. It involves the excision of a short single-stranded DNA segment containing the damage, followed by synthesis to restore the original sequence.
3. **Mismatch Repair (MMR):** This system corrects errors that escape proofreading during DNA replication, particularly those involving base-base mismatches.
4. **Homologous Recombination (HR) and Non-Homologous End Joining (NHEJ):** These pathways address double-strand breaks (DSBs), with HR providing an accurate repair mechanism utilizing homologous sequences and NHEJ offering a more rapid but error-prone approach [43].

The proficiency and fidelity of these DNA repair systems are crucial in maintaining genomic integrity. Failure in any of these pathways can lead to the accumulation of mutations.

Consequences of DNA Repair Failure

The consequences of DNA repair failure can be vast and multifaceted, impacting not only individual cells but also multicellular organisms and ecosystems.

1. **Cellular Consequences:**
   The immediate effect of defective DNA repair is the increased mutation rate within affected cells. This can lead to a range of cellular outcomes, including senescence (a state of permanent cell cycle arrest), apoptosis (programmed cell death), and uncontrolled cell proliferation. For instance, cancer cells often exhibit deficiencies in DNA repair mechanisms, such as the loss of MMR, leading to microsatellite instability and promoting tumorigenesis. These mutations may confer growth advantages to the cancerous cells, facilitating malignancy [44].
2. **Impact on Organismal Health:**
   At the organismal level, inherited mutations in DNA repair genes can result in genetic disorders and predispose individuals to various diseases. Conditions such as xeroderma pigmentosum, where NER is defective, lead to heightened sensitivity to sunlight and a significantly increased risk of skin cancer. Similarly, mutations in BRCA1 and BRCA2 genes impair homologous recombination, resulting in a predisposition to breast and ovarian cancers. The accumulating evidence linking DNA repair deficiencies with cancer highlights the importance of genomic stability in the prevention of disease [45].
3. **Evolutionary Implications:**
   While excessive mutations can be deleterious, they can also drive evolutionary change by introducing genetic diversity within populations. Some mutations may confer advantageous traits in certain environments, allowing for natural selection to act upon them. In the long term, however, an organism with a faulty DNA repair system risks accumulating deleterious mutations that may compromise survival. Thus, while mutagenesis can facilitate adaptation, excess mutations due to repair failure may have the opposite effect, undermining the organism's fitness [46].
4. **Environmental Consequences:**
   On a broader scale, ecosystems are also impacted by mutagenesis and the failure of DNA repair systems. For example, polycyclic aromatic hydrocarbons (PAHs) from environmental pollutants can induce genotoxic damage, leading to mutations in wildlife populations. This could result in declining biodiversity, altered ecological interactions, and impaired ecosystem services. Furthermore, such mutations can compromise the adaptability of these populations in the face of changing environmental conditions [47].

Implications for Cancer Development and Radiotherapy:

Cancer has long been recognized as one of the most significant health challenges of our time. With millions of new cases diagnosed annually, understanding the implications for cancer development and treatment strategies, particularly radiotherapy, is crucial in advancing oncological care [48]. Cancer is characterized by uncontrolled cell growth and proliferation, which can arise due to a combination of genetic, environmental, and lifestyle factors. At the molecular level, cancer development often involves mutations in key regulatory genes, including oncogenes, tumor suppressor genes, and genes involved in DNA repair. These mutations can result from various sources, such as UV radiation, chemicals, viruses, and inherited genetic predispositions [48].

The carcinogenic process typically unfolds in multiple stages: initiation, promotion, and progression. During initiation, genetic mutations occur in critical genes. Promotion refers to the selective growth of these initiated cells, often influenced by factors such as inflammation, hormones, and growth factors. Finally, progression involves further genetic changes and adaptations that facilitate invasive behavior, metastasis, and resistance to apoptotic signals. Understanding these processes enables researchers and clinicians to identify potential intervention points in cancer's multi-step progression [49].

Radiotherapy is one of the cornerstone modalities used in cancer treatment, often employed alongside surgery, chemotherapy, and immunotherapy. Its primary mechanism of action involves delivering ionizing radiation to destroy cancer cells while minimizing damage to the surrounding healthy tissue. The two main types of radiotherapy are external beam radiation therapy (EBRT) and brachytherapy. EBRT delivers radiation from outside the body, while brachytherapy involves placing radioactive sources directly inside or near the tumor [50].

The effectiveness of radiotherapy stems from its ability to induce DNA damage within cancer cells. Tumor cells are generally less able to effectively repair DNA damage compared to normal cells, which makes them more susceptible to the effects of radiation. The primary types of DNA damage induced by radiotherapy are double-strand breaks, single-strand breaks, and DNA cross-links. These lesions can lead to cell cycle arrest, apoptosis, or senescence, thereby reducing tumor size and limiting metastatic potential.

However, the efficacy of radiotherapy is influenced by various factors, including tumor type, tumor microenvironment, and the presence of hypoxic regions. Many solid tumors exhibit areas of hypoxia, where oxygen availability is low, which can render them more resistant to radiation therapy. Therefore, understanding the biological characteristics of tumors is crucial in optimizing treatment regimens [51].

While radiotherapy is a potent treatment modality, its applications also imply certain risks and considerations. One of the significant implications is the potential for the development of secondary cancers as a consequence of radiation exposure. The risk of radiation-induced malignancies has been documented in patients who receive high doses of radiation, particularly in pediatric populations and those treated for childhood cancers. These secondary cancers often occur years after the initial treatment and can be challenging to manage [52].

Moreover, the concept of radiotherapy-induced genomic alterations adds another layer of complexity to cancer management. Some studies suggest that radiotherapy can lead not only to targeted cell death but also to changes in the tumor microenvironment or even modifications in the cancer genome itself. These changes could potentially enable tumor cells to acquire enhanced features, such as increased aggressiveness or the ability to evade immune responses. Understanding the long-term implications of these alterations is essential for developing comprehensive treatment protocols and surveillance strategies for cancer survivors [53].

As we move forward, ongoing research and technological advancements hold great promise for improving radiotherapy's effectiveness and safety. Innovations such as image-guided radiation therapy (IGRT) and intensity-modulated radiation therapy (IMRT) aim to enhance the precision of radiation delivery while minimizing exposure to surrounding normal tissues. Furthermore, the advent of stereotactic body radiotherapy (SBRT) allows for delivering high doses of radiation to tumors in fewer fractions, which may improve patient outcomes and reduce the overall treatment burden [54].

In addition to technological advancements, there is a growing interest in integrating radiotherapy with other treatment modalities, such as immunotherapy. Emerging evidence suggests that

radiation may enhance the antitumor immune response, making it a valuable companion therapy alongside immune checkpoint inhibitors. Ongoing clinical trials are assessing the synergistic effects of combining these modalities, aiming to improve response rates and, ultimately, survival outcomes for patients with various cancer types [55].

Conclusion:

In conclusion, the study of cellular responses to ionizing radiation reveals the intricate and dynamic nature of DNA repair mechanisms that play a critical role in maintaining genomic integrity. Ionizing radiation poses a significant threat to DNA, leading to various forms of damage that can disrupt cellular functions and ultimately lead to mutations. The cellular response involves multiple repair pathways, including base excision repair, nucleotide excision repair, and homologous recombination, each tailored to address specific types of damage. Additionally, the activation of signaling pathways, particularly the p53 tumor suppressor pathway, is essential for regulating the cell cycle and determining cell fate following DNA injury.

Despite the effectiveness of these repair mechanisms, the persistence of unrepaired or incorrectly repaired DNA can result in mutagenesis, contributing to the development of cancer. Understanding these processes not only enhances our knowledge of fundamental cellular biology but also has vital implications for improving radiotherapy techniques and developing strategies to mitigate radiation-induced damage. Future research should focus on elucidating the precise molecular interactions within these pathways and exploring novel therapeutic approaches that can enhance DNA repair capacity, thereby reducing the risk of cancer associated with ionizing radiation exposure. Ultimately, a deeper understanding of these cellular responses can inform public health policies and guide interventions in clinical settings.

References:

1. Ahmad S.S., Duke S., Jena R., Williams M.V., Burnet N.G. Advances in radiotherapy. BMJ. 2012;345:102. doi: 10.1136/bmj.e7765.
2. Verellen D., Ridder M.D., Linthout N., Tournel K., Soete G., Storme G. Innovations in image-guided radiotherapy. Nat. Rev. Cancer. 2007;7:949–960. doi: 10.1038/nrc2288.
3. Wenz F., Tiefenbacher U., Willeke F., Weber K.J. The search for therapeutic gain in radiation oncology. Onkologie. 2001;24(Suppl. 5):51–55. doi: 10.1159/000055187.
4. Baskar R., Lee K.A., Yeo R., Yeoh K.W. Cancer and radiation therapy: Current advances and future directions. Int. J. Med. Sci. 2012;9:193–199. doi: 10.7150/ijms.3635.
5. Herskind C., Wenz F. Radiobiological aspects of intraoperative tumour-bed irradiation with low-energy X-rays (LEX-IORT). Transl. Cancer Res. 2014;3:3–17.
6. Hall E.J., Giaccia A.J. Radiobiology for the Radiologist. 7th ed. Lippincott Williams & Wilkins; Philadelphia, PA, USA: 2012. p. 576.
7. Lo S.S., Fakiris A.J., Chang E.L., Mayr N.A., Wang J.Z., Papiez L., Teh B.S., McGarry R.C., Cardenes H.R., Timmerman R.D. Stereotactic body radiation therapy: A novel treatment modality. Nat. Rev. Clin. Oncol. 2010;7:44–54. doi: 10.1038/nrclinonc.2009.188.
8. Purdy J.A. Dose to normal tissues outside the radiation therapy patient's treated volume: A review of different radiation therapy techniques. Health Phys. 2008;95:666–676. doi: 10.1097/01.HP.0000326342.47348.06.
9. Bhide S.A., Nutting C.M. Recent advances in radiotherapy. BMC Med. 2010;8. doi: 10.1186/1741-7015-8-25.
10. Tipton K., Launders J.H., Inamdar R., Miyamoto C., Schoelles K. Stereotactic body radiation therapy: Scope of the literature. Ann. Intern. Med. 2011;154:737–745. doi: 10.7326/0003-4819-154-11-201106070-00343.
11. Bentzen S.M., Constine L.S., Deasy J.O., Eisbruch A., Jackson A., Marks L.B., Ten Haken R.K., Yorke E.D. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An introduction to the scientific issues. Int. J. Radiat. Oncol. Biol. Phys. 2010;76:S3–S9. doi: 10.1016/j.ijrobp.2009.09.040.

12. West C.M., Davidson S.E., Hendry J.H., Hunter R.D. Prediction of cervical carcinoma response to radiotherapy. Lancet. 1991;338:818. doi: 10.1016/0140-6736(91)90700-Y.
13. Bentzen S.M., Heeren G., Cottier B., Slotman B., Glimelius B., Lievens Y., van den Bogaert W. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: The ESTRO QUARTS project. Radiother. Oncol. 2005;75:355–365. doi: 10.1016/j.radonc.2004.12.007.
14. Peters L.J., Withers H.R., Thames H.D., Jr., Fletcher G.H. Tumor radioresistance in clinical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1982;8:101–108. doi: 10.1016/0360-3016(82)90392-3.
15. Emami B., Lyman J., Brown A., Coia L., Goitein M., Munzenrider J.E., Shank B., Solin L.J., Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 1991;21:109–122. doi: 10.1016/0360-3016(91)90171-Y.
16. Holthusen H. Erfahrungen über die verträglichkeit von röntgenstrahlen und deren nutzanwendung zur verhütung von schaden. Strahlenther. Onkol. 1936;57:30–36.
17. Herskind C., Westergaard O. Inactivation of a single eucaryotic gene irradiated in vitro in transcriptionally active chromatin form. Radiat. Res. 1986;106:331–344. doi: 10.2307/3576741.
18. Herskind C., Westergaard O. Variable protection by OH scavengers against radiation-induced inactivation of isolated transcriptionally active chromatin: The influence of secondary radicals. Radiat. Res. 1988;114:28–41. doi: 10.2307/3577141.
19. Delaney G., Jacob S., Featherstone C., Barton M. The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104:1129–1137. doi: 10.1002/cncr.21324.
20. Maier P., Wenz F., Herskind C. Radioprotection of normal tissue cells. Strahlenther. Onkol. 2014;190:745–752. doi: 10.1007/s00066-014-0637-x.

21. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104:1129–1137. doi: 10.1002/cncr.21324.

22. Constantinou A, Chen XB, McGowan CH, West SC. Holliday junction resolution in human cells: Two junction endonucleases with distinct substrate specificities. EMBO J. 2002;21:5577–5585. doi: 10.1093/emboj/cdf554.

23. Brown LC, Mutter RW, Halyard MY. Benefits, risks, and safety of external beam radiation therapy for breast cancer. Int J Womens Health. 2015;7:449–458. doi: 10.2147/IJWH.S55552.

24. Chistiakov DA, Voronova NV, Chistiakov PA. Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients. Acta Oncol. 2008;47:809–824. doi: 10.1080/02841860801885969.

25. Chen H, Lisby M, Symington L. RPA coordinates DNA end resection and prevents formation of DNA hairpins. Mol Cell. 2013;50:589–600. doi: 10.1016/j.molcel.2013.04.032.

26. Capp JP, Boudsocq F, Bertrand P, Laroche-Clary A, Pourquier P, Lopez BS, Cazaux C, Hoffmann JS, Canitrot Y. The DNA polymerase λ is required for the repair of non-compatible DNA double strand breaks by NHEJ in mammalian cells. Nucleic Acids Res. 2006;34:2998–3007. doi: 10.1093/nar/gkl380.

27. Davis AJ, Chen BPC, Chen DJ. DNA-PK: A dynamic enzyme in a versatile DSB repair pathway. DNA Repair. 2014;17:21–29. doi: 10.1016/j.dnarep.2014.02.020.

28. Azqueta A, Slyskova J, Langie SAS, Gaivão ION, Collins A. Comet assay to measure DNA repair: Approach and applications. Front Genet. 2014;5:1–8. doi: 10.3389/fgene.2014.00288.

29. Barnett GC, West CML, Dunning AM, Elliott RM, Coles CE, Pharoah PDP, Burnet NG. Normal tissue reactions to radiotherapy: Towards tailoring treatment dose by genotype. Nat Rev Cancer. 2009;9:134–142. doi: 10.1038/nrc2587.

30. Aparicio T, Baer R, Gautier J. DNA double-strand break repair pathway choice and cancer. DNA Repair. 2014;19:169–175. doi: 10.1016/j.dnarep.2014.03.014.

31. Bétermier M, Bertrand P, Lopez BS. Is non-homologous end-joining really an inherently error-prone process. PLoS Genet. 2014;10. doi: 10.1371/journal.pgen.1004086.

32. Bosviel R, Garcia S, Lavediaux G, Michard E, Dravers M, Kwiatkowski F, Bignon Y, Bernard-Gallon DJ. BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls. Cancer Epidemiol. 2012;36:177–182. doi: 10.1016/j.canep.2012.02.001.

33. Bernstein NK, Williams RS, Rakovszky ML, Cui D, Green R, Karimi-Busheri F, Mani RS, Galicia S, Koch CA, Cass CE, et al. The molecular architecture of the mammalian DNA repair enzyme, polynucleotide kinase. Mol Cell. 2005;17:657–670. doi: 10.1016/j.molcel.2005.02.012.

34. Deckbar D, Jeggo PA, Löbrich M. Understanding the limitations of radiation-induced cell cycle checkpoints. Crit Rev Biochem Mol Biol. 2011;46:271–283. doi: 10.3109/10409238.2011.575764.

35. Brollo J, Kneubil MC, Botteri E, Rotmensz N, Duso BA, Fumagalli L, Locatelli MA, Criscitiello C, Lohsiriwat V, Goldhirsch A, et al. Locoregional recurrence in patients with HER2 positive breast cancer. Breast. 2013;22:856–862. doi: 10.1016/j.breast.2013.03.010.

36. Boehden GS, Su S, Rimek A, Preuss U, Scheidtmann K, Wiesmu L. DNA substrate dependence of p53-mediated regulation of double-strand break repair. Mol Cell Biol.

37. Hwang M, Yong C, Moretti L, Lu B (2007) Zebrafish as a Model System to Screen Radiation Modifiers. Curr Genomics 8(6): 360–9.

38. Gagnaire B, Cavalié I, Pereira S, Floriani M, Dubourg N, Camilleri V, Adam-Guillermin C (2015) External gamma irradiation-induced effects in early-life stages of zebrafish, Danio rerio. Aquat Toxicol 169: 69–78.

39. Hirao A, Kong Y-Y, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, Mak TW (2000) DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science, 287(5459): 1824–7.

40. Anderson JA, Lewellyn AL, Maller JL (1997) Ionizing radiation induces apoptosis and elevates cyclin A1-Cdk2 activity before but not after the midblastula transition in Xenopus. Mol Biol Cell 8(7): 1195–206.

41. De Santis M, Cesari E, Nobili E, Straface G, Cavaliere AF, Caruso A (2007) Radiation effects on development. Birth Defects Res C Embryo Today Rev 81(3): 177–82.

42. Heyer BS, MacAuley A, Behrendtsen O, Werb Z (2000) Hypersensitivity to DNA damage leads to increased apoptosis during early mouse development. Genes Dev 14(16): 2072–84.

43. Filion TM, Qiao M, Ghule PN, Mandeville M, van Wijnen AJ, Stein JL, Lian JB, Altieri DC, Stein GS (2009) Survival responses of human embryonic stem cells to DNA damage. J Cell Physiol 220(3): 586–92.

44. Ikegami R, Rivera-Bennetts AK, Brooker DL, Yager TD (1997) Effect of inhibitors of DNA replication on early zebrafish embryos: evidence for coordinate activation of multiple intrinsic cell-cycle checkpoints at the mid-blastula transition. Zygote 5(02): 153–75.

45. Hill AJ, Teraoka H, Heideman W, Peterson RE (2005) Zebrafish as a model vertebrate for investigating chemical toxicity. Toxicol Sci 86(1): 6–19.

46. Bladen CL, Lam WK, Dynan WS, Kozlowski DJ (2005) DNA damage response and Ku80 function in the vertebrate embryo. Nucleic Acids Res 33(9): 3002–10.

47. Brownlie A, Donovan A, Pratt SJ, Paw BH, Oates AC, Brugnara C, Witkowska HE, Sassa S, Zon LI (1998) Positional cloning of the zebrafish sauternes gene: a model for congenital sideroblastic anaemia. Nat Genet 20(3): 244–50.

48. Gagnaire B, Cavalié I, Pereira S, Floriani M, Dubourg N, Camilleri V, Adam-Guillermin C (2015) External gamma irradiation-induced effects in early-life stages of zebrafish, Danio rerio. Aquat Toxicol 169: 69–78.

49. Bladen CL, Navarre S, Dynan WS, Kozlowski DJ (2007) Expression of the Ku70 subunit (XRCC6) and protection from low dose ionizing radiation during zebrafish embryogenesis. Neurosci Lett 422(2): 97–102.

50. Geiger GA, Parker SE, Beothy AP, Tucker JA, Mullins MC, Kao GD (2006) Zebrafish as a "biosensor"? Effects of ionizing radiation and amifostine on embryonic viability and development. Cancer Res 66(16): 8172–81.

51. Dooley K, Zon LI (2000) Zebrafish: a model system for the study of human disease. Curr Opin Genet Dev 10(3): 252–6.

52. Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA (1999) Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci USA 96(3): 1002–7.

53. Adiga SK, Toyoshima M, Shimura T, Takeda J, Uematsu N, Niwa O (2007) Delayed and stage specific phosphorylation of H2AX during preimplantation development of γ-irradiated mouse embryos. Reproduction 133(2): 415–22.

54. Hurem S, Martín LM, Brede DA, Skjerve E, Nourizadeh-Lillabadi R, Lind OC, Christensen T, Berg V, Teien H, Salbu B, Oughton DH, Aleström P, Lyche JL (2017) Dose-dependent effects of gamma radiation on the early zebrafish development and gene expression. PLoS ONE 12(6): e0179259.

55. Hill AJ, Teraoka H, Heideman W, Peterson RE (2005) Zebrafish as a model vertebrate for investigating chemical toxicity. Toxicol Sci 86(1): 6–19.